• 1
    Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2002 [based on November 2004 SEER data submission; posted to the SEER web site 2005]. Bethesda: National Cancer Institute, 2005.
  • 2
    [No authors listed.] International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15: 594603.
  • 3
    Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995; 13: 11771187.
  • 4
    Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol. 2002; 20: 262271.
  • 5
    Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998; 16: 6571.
  • 6
    Hollender A, Stenwig EA, Ous S, Fossa SD. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy. Eur Urol. 1997; 31: 141147.
  • 7
    Onozawa M, Kawai K, Yamamoto T, et al. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer. Int J Urol. 2004; 11: 535541.
  • 8
    Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003; 21: 33103317.
  • 9
    Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol. 1985; 3: 326335.
  • 10
    Fizazi K, Do KA, Wang X, Finn, L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rates in disseminated testicular non-seminomatous germ-cell tumors: final results of a Phase III randomized trial. Ann Oncol. 2002; 13: 125134.
  • 11
    Fizazi K, Do KA, Wang X, Finn L, Kim J, Daliani D. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors. Br J Cancer. 2002; 86: 15551560.
  • 12
    Prow DM, Amato RJ, Jones DM, Logothetis CJ. Carboplatin, etoposide, and bleomycin (CEB) combination chemotherapy for the treatment of small volume (SV) metastatic non-seminomatous germ cell tumor of the testis (NSGCT). Proc Am Soc Clin Oncol. 1997; 16: 340a. Abstract 1217.
  • 13
    Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005; 23: 27812788.
  • 14
    Kaplan EL, Meier EP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 15
    Cox D. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187220.
  • 16
    Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis.Medical Research Council Testicular Tumour Working Party. Cancer. 1998; 83: 14091419.
  • 17
    Fossa SD, Aass N, Ous S, et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol. 1989; 142: 12391242.
  • 18
    Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004; 15: 13771399.
  • 19
    van Dijk MR, Steyerberg EW, Stenning SP, Dusseldorp E, Habbema JD. Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer. 2004; 90: 11761183.
  • 20
    Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol. 2001; 19: 26472657.